ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements
Norris Medicines Limited intimated a prior board meeting on 14 Nov 2026 to consider unaudited standalone quarterly results for September 2026. Trading window closed from 01 Oct to 16 Nov 2026.
Norris Medicines Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Norris Medicines Limited held its 35th Annual General Meeting on September 29, 2026, where members transacted various ordinary and special business items.
Norris Medicines Limited has filed its 35th Annual Report for the financial year 2025-26, including the notice of its upcoming Annual General Meeting.
Norris Medicines approved the Directors' Report, Annual Report, and convening of the 35th Annual General Meeting for September 29, 2026.
Norris Medicines Ltd reported revenue from operations of ₹0.9 Cr (-40.0% YoY) and a net loss of ₹0.4 Cr for Q1 FY27.
Norris Medicines Limited has scheduled a board meeting for August 14, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.
Norris Medicines Limited has appointed Mr. Iqubal Ismail Patel as the Chief Financial Officer and Key Managerial Personnel, effective July 30, 2026.
Norris Medicines Ltd filed its quarterly shareholding pattern as of June 30, 2026. The document lists promoter and public holdings per Regulation 31.
Norris Medicines Ltd reported revenue from operations of ₹1.4 Cr (-48.1% YoY) and net profit of ₹0.1 Cr for Q4 FY26.
Norris Medicines Limited approved audited financial results for the year ended March 31, 2026. The company also appointed M/s. Dhiren Y Parikh & Co. as Internal Auditors.
Norris Medicines scheduled a board meeting for May 30, 2026, to approve audited FY26 financial results. The trading window remains closed until 48 hours post-declaration.